Charles River Laboratories (CRL) cash flow statement

Life Sciences Tools & Services · NYSE · Health Care

$332.16 -1.00% Close Nov 17, 2026 Live

TrendArc score 45 of 100 · Health 4.5 · Momentum 8.4 · Moat 5.0 · scored Nov 17, 2026 · How the score works

Free cash flow, fiscal year to December 27, 2025

$518 million

up 3.4% from the year before

Charles River Laboratories generated $518 million of free cash flow in the fiscal year to December 2025: $738 million of cash from operations less $219 million of capital spending. That was 12.9% of revenue, against 12.4% the year before. Over the last four quarters, to September 26, 2026, it was $400 million.

What stands out

  • Net share repurchases of $360 million came to 69% of free cash flow in the fiscal year to December 2025.

Each sentence is written by a fixed rule from the figures on this page.

Free cash flow and net income, the last 10 fiscal years

-$200M$200M$400M$600M2016201720182019202020212022202320242025$262MFree cash flow $518MNet income -$144M-$200M$200M$400M$600M20172019202120232025Free cash flow $518MNet income -$144M

Fiscal years, each labelled by the calendar year it ended in. Every figure is in the statement below.

Where the cash wentFiscal year to December 27, 2025

  1. Cash from operations 0.74
  2. Capital spending -0.22
  3. Free cash flow 0.52
  4. Investments bought and sold, net 0.01
  5. Net share repurchases -0.36
  6. Debt and other -0.16
  7. Net change in cash 0.01

In billions of US dollars. Outflows are grey, not red: a buyback is not a loss. "Debt and other" closes the gap to the reported change in cash. Buying marketable securities moves cash into short-term investments; the balance sheet shows both.

Cash flow statement, the last 10 fiscal years

In billions of US dollars. Each column is a fiscal year, named by the month it ended; the first column adds up the last four quarters. Cash paid out is a negative number.
Fiscal year toLast 4 quarters
to Sep 2026
Dec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
Operating activities
Net income-0.140.020.470.490.390.360.250.230.120.15
Depreciation and amortisation0.400.360.310.300.270.230.200.160.130.13
Stock-based pay0.080.070.070.070.070.070.060.060.050.040.04
Working capital and other items0.410.28-0.18-0.240.03-0.11-0.030.010.02-0.01
Cash from operations0.620.740.730.680.620.760.550.480.440.320.32
Investing activities
Capital spending-0.22-0.22-0.23-0.32-0.32-0.23-0.17-0.14-0.14-0.08-0.06
Businesses bought and sold, net0.00-0.06-0.25-0.28-1.22-0.45-0.54-0.850.00-0.69
Investments bought and sold, net0.010.040.010.000.010.010.000.040.010.05
Cash from investing-0.21-0.25-0.56-0.61-1.44-0.60-0.68-0.96-0.07-0.69
Financing activities
Debt issued or repaid, net-0.12-0.41-0.080.020.670.030.230.54-0.140.38
Shares issued less bought back-0.29-0.36-0.100.00-0.010.000.020.020.02-0.070.01
Dividends paid0.000.000.000.000.000.000.000.000.000.000.00
Other financing-0.05-0.04-0.01-0.050.00-0.01-0.010.000.00-0.01
Cash from financing-0.54-0.55-0.09-0.040.670.050.230.56-0.210.38
Exchange rate effect0.02-0.020.010.030.020.000.01-0.010.010.00
Net change in cash0.01-0.080.04-0.010.01-0.010.040.030.050.00
Free cash flow
Free cash flow0.400.520.500.370.290.530.380.340.300.240.26
Free cash flow margin10.0%12.9%12.4%8.8%7.4%15.0%13.0%13.0%13.3%12.7%15.6%
Free cash flow per share$10.46$9.72$7.10$5.75$10.35$7.51$6.85$6.14$4.85$5.46

Shares issued less bought back is the cash from shares sold less the cash paid for shares bought back (negative when more was bought back), and includes tax withheld when employees' shares vest. Working capital and other items is cash from operations less net income, depreciation and amortisation, and stock-based pay (calculated by TrendArc). Company filings as standardised by Tiingo; calculations by TrendArc. Rebuilt nightly.

Charles River Laboratories against its peers

CompanyFiscal year toFree cash flowFree cash flow margin
Bio-TechneTECH Jun 2026$263M21.7%
IlluminaILMN Dec 2025$931M21.4%
Mettler ToledoMTD Dec 2025$849M21.1%
WatersWAT Dec 2025$543M17.1%
Agilent TechnologiesA Oct 2025$1.15B16.6%
IQVIAIQV Dec 2025$2.13B13.0%
Charles River LaboratoriesCRL Dec 2025$518M12.9%
Peer median19.1%

Each company's newest fiscal year; some end in other months. The peers are the stock card's peer group.

Next

Follow Charles River Laboratories with a free account.

A watchlist, price alerts and saved chart layouts. No card needed.

Sign up free

No forecast, no recommendation. This page describes Charles River Laboratories from published data; it is not advice to buy, sell or hold any security.

Figures as of the close on Nov 17, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.

The TrendArc score, from 0 to 100, combines three pillars measured from published data, Health (business quality over the last twelve months), Momentum (the price against its moving averages, its 52-week high and the market) and Moat (durability over five years), with the share price's long-run trend. It describes the company as it stands today. It is not a forecast or a recommendation.